Table 5 Cancer characteristics.

Braithwaite [21]

66–74 vs 75–89

Positive lymph nodes

Charlson Score=0 & 1-year screen interval: 21.2% vs 16.3%;

Charlson Score=0 & 2-year screen interval: 20.6% vs 15.7%;

Charlson Score=1 & 1-year screen interval: 24.1% vs 16.6%;

Charlson Score=1 & 2-year screen interval: 17.8% vs 12.4%.

Destounis [24]

No comparison

Positive lymph nodes

7%

Erbas [25]

40–49 vs 50–69 vs 70–74 vs ≥75

Invasive cancer node positive (%)

28.99% vs 19.51% vs 15.27% vs 9.45% (p < 0.001)

Interval cancer node positive (%)

75.40% vs 84.26% vs 71.21% vs 59.26% (p < 0.001)

Malmgren [33]

Mammography v physician v patient detected

Lymph nodes positive

MgD 12% vs PtD+PhysD 38%

Braithwaite [21]

66–74 vs 75–89

Advanced stage (IIB-IV)

Charlson Score=0 & 1-year screen interval: 12.0% vs 9.4%;

Charlson Score=0 & 2-year screen interval: 10.9% vs 10.7%;

Charlson Score=1 & 1-year screen interval: 15.8% vs 11.7%;

Charlson Score=1 & 2-year screen interval: 11.1% vs 5.7%.

Erbas [25]

40–49 vs 50–69 vs 70–74 vs 75 and older

Invasive cancer grade III (%)

20.29% vs 18.10% vs 15.06% vs 13.39% (p = 0.05)

Interval cancer grade III (%)

49.06% vs 38.18% vs 30.91% vs 45.45% (p = 0.06)

Hartman [27]

No comparison

Stage

Stage was known for 17 of 26 women: 88% (15/17) had stage 0 (n = 3) or stage I (n = 12) disease and 12% (n = 2) had stage II disease. Stage 3: 0. Unknown stage: 9 (35%)

Grade

Unknown: 1;

High: 5;

Intermediate to high: 3;

Intermediate: 11; Low to intermediate: 3, Low: 3.

McCarthy [35]

Non users v regular users

Late-stage disease

75–84 (n = 1790) OR 3.64 (2.96-4.48)

85+ (n = 455) OR 6.87 (3.97–11.90)

Adjusted for age at diagnosis, race, marital status, income of ZIP code and comorbidity

Vyas [48]

70–74 v 45–79 v 80 and older

Diagnosis at insitu stage

70–74: 1 (reference group)

75–79: 0.97 (0.84–1.11)

80+: 0.79 (0.69–0.90)

Diagnosis at local stage

70–74: 1(reference group)

75–79: 1.02 (0.90–1.16)

80+: 1.13 (1.00–1.26)

Diagnosis at regional stage

70–74: 1(reference group)

75–79: 1.03 (0.90–1.17)

80+: 1.00 (1.88–1.12)

Erbas [25]

40–49 vs 50–69 vs 70–74 vs 75 and older

Invasive cancer mean size (mm)

17.2 vs 13.88 vs 13.40 vs 13.66 (p = 0.08)

Invasive cancer mean size (mm) by time since previous negative screen

<27 months: 16.97 vs 13.66 vs 13.35 vs 12.71; 27–36 months: 17.25 vs 14.17 vs 13.08 vs 12.41; ≥37 months: 17.51 vs 16.91 vs 15.21 vs 17.46

Interval cancer mean size (mm)

20.64 vs 21.39 vs 18.61 vs 20.75

Malmgren [33]

Mammography detected v physician detected/ patient detected

Mean tumour size (cm)

3.02 (pt/phys) v 1.53 (mammo) p < 0.001

Randolph [38]

65–74 v 75 and older

Mean tumour size (adjusted 69–74 v 75 + - non, single, regular user)

25.5, 19.3, 17.4 v 28.9, 20.6, 16.9.

VanDijck [45]

First screen, repeat screen, interval CA or non-participant

Tumour size of invasive cancers according to detection round First screening: Repeat screen: Interval: non-participants

Median (25-75 centile); 20(14–27): 12 (7–20): 20 (13–25): 30(20–40)